143 related articles for article (PubMed ID: 31426129)
41. Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.
Seetharam SM; Liu Y; Wu J; Fechter L; Murugesan K; Maecker H; Gotlib J; Zehnder J; Paulmurugan R; Krishnan A
Blood Adv; 2023 Sep; 7(18):5433-5445. PubMed ID: 37315179
[TBL] [Abstract][Full Text] [Related]
42. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
43. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
Lucijanic M; Livun A; Tomasovic-Loncaric C; Stoos-Veic T; Pejsa V; Jaksic O; Prka Z; Kusec R
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
[TBL] [Abstract][Full Text] [Related]
44. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
Moliterno AR; Hankins WD; Spivak JL
N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
[TBL] [Abstract][Full Text] [Related]
45. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
46. Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications.
Šefer D; Bižić-Radulović S; Kraguljac-Kurtović N; Bogdanović A; Čokić V; Miljić P; Beleslin-Čokić B; Knežević V; Mitrović-Ajtić O; Leković D; Gotić M
Int J Lab Hematol; 2017 Feb; 39(1):21-31. PubMed ID: 28025866
[TBL] [Abstract][Full Text] [Related]
47. Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm.
Nguyen TK; Morse SJ; Fleischman AG
J Vis Exp; 2016 Dec; (118):. PubMed ID: 28060252
[TBL] [Abstract][Full Text] [Related]
48. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations.
Barraco D; Cerquozzi S; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2017 Mar; 7(3):e538. PubMed ID: 28282034
[TBL] [Abstract][Full Text] [Related]
49. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
[TBL] [Abstract][Full Text] [Related]
50. Global coagulation in myeloproliferative neoplasms.
Tripodi A; Chantarangkul V; Gianniello F; Clerici M; Lemma L; Padovan L; Gatti L; Mannucci PM; Peyvandi F
Ann Hematol; 2013 Dec; 92(12):1633-9. PubMed ID: 23820940
[TBL] [Abstract][Full Text] [Related]
51. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis.
Leimkühler NB; Gleitz HFE; Ronghui L; Snoeren IAM; Fuchs SNR; Nagai JS; Banjanin B; Lam KH; Vogl T; Kuppe C; Stalmann USA; Büsche G; Kreipe H; Gütgemann I; Krebs P; Banz Y; Boor P; Tai EW; Brümmendorf TH; Koschmieder S; Crysandt M; Bindels E; Kramann R; Costa IG; Schneider RK
Cell Stem Cell; 2021 Apr; 28(4):637-652.e8. PubMed ID: 33301706
[TBL] [Abstract][Full Text] [Related]
52. Biology and management of idiopathic myelofibrosis.
Smith BD; Moliterno AR
Curr Opin Oncol; 2001 Mar; 13(2):91-4. PubMed ID: 11224705
[TBL] [Abstract][Full Text] [Related]
53. [Atypical myeloproliferative disorders: a study on 3 cases showing pancytopenia, marrow fibrosis and the absence of splenomegaly].
Yoshida Y; Yamagishi M; Fukuhara S; Sawada H; Ohkuma M; Uchino H; Nakamura T
Rinsho Ketsueki; 1984 Mar; 25(3):383-92. PubMed ID: 6471435
[No Abstract] [Full Text] [Related]
54. [Role of PDGF on myeloproliferative disorders].
Kimura A; Katoh O; Kuramoto A
Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
[No Abstract] [Full Text] [Related]
55. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
Nagao T; Yonekura S
Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
[No Abstract] [Full Text] [Related]
56. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
Kvasnicka HM
Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
[TBL] [Abstract][Full Text] [Related]
57. Platelet function in preleukaemia.
Lintula R; Rasi V; Ikkala E; Borgström GH; Vuopio P
Scand J Haematol; 1981 Jan; 26(1):65-71. PubMed ID: 7466320
[TBL] [Abstract][Full Text] [Related]
58. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
Okuma M
Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
[No Abstract] [Full Text] [Related]
59. [Acute myeloid leukemia with megakaryocytic predominance and malignant megakaryocyte proliferation. Apropos of 3 cases].
Nigro M; Ascari E; Compagnoni A; Menestrina F
Ann Anat Pathol (Paris); 1979; 24(2):171-84. PubMed ID: 294156
[TBL] [Abstract][Full Text] [Related]
60. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
